Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 4 de 4
Filter
Add more filters










Database
Language
Publication year range
1.
J Neurosci ; 35(43): 14467-75, 2015 Oct 28.
Article in English | MEDLINE | ID: mdl-26511239

ABSTRACT

The mammalian striatum controls sensorimotor and psychoaffective functions through coordinated activities of its two striatonigral and striatopallidal output pathways. Here we show that retinoic acid receptor ß (RARß) controls development of a subpopulation of GABAergic, Gad65-positive striatonigral projection neurons. In Rarb(-/-) knock-out mice, concomitant reduction of Gad65, dopamine receptor D1 (Drd1), and substance P expression at different phases of prenatal development was associated with reduced number of Drd1-positive cells at birth, in contrast to normal numbers of striatopallidal projection neurons expressing dopamine receptor D2. Fate mapping using BrdU pulse-chase experiments revealed that such deficits may originate from compromised proliferation of late-born striosomal neurons and lead to decreased number of Drd1-positive cells retaining BrdU in postnatal day (P) 0 Rarb(-/-) striatum. Reduced expression of Fgf3 in the subventricular zone of the lateral ganglionic eminence (LGE) at embryonic day 13.5 may underlie such deficits by inducing premature differentiation of neuronal progenitors, as illustrated by reduced expression of the proneural gene Ascl1 (Mash1) and increased expression of Meis1, a marker of postmitotic LGE neurons. In agreement with a critical role of FGF3 in this control, reduced number of Ascl1-expressing neural progenitors, and a concomitant increase of Meis1-expressing cells, were observed in primary cell cultures of Rarb(-/-) LGE. This defect was normalized by addition of fibroblast growth factor (FGF). Such data point to role of Meis1 in striatal development, also supported by reduced neuronal differentiation in the LGE of Meis1(-/-) embryos. Our data unveil a novel mechanism of development of striatonigral projection neurons involving retinoic acid and FGF, two signals required for positioning the boundaries of Meis1-expressing cells.


Subject(s)
Corpus Striatum/physiology , Fibroblast Growth Factors/physiology , Homeodomain Proteins/physiology , Neoplasm Proteins/physiology , Neurons/physiology , Receptors, Retinoic Acid/physiology , Substantia Nigra/physiology , Animals , Antimetabolites/pharmacology , Bromodeoxyuridine/pharmacology , Corpus Striatum/cytology , Corpus Striatum/embryology , Female , Fibroblast Growth Factor 3/metabolism , Glutamate Decarboxylase/metabolism , Mice , Mice, Inbred C57BL , Mice, Knockout , Myeloid Ecotropic Viral Integration Site 1 Protein , Neurogenesis/genetics , Neurogenesis/physiology , Pregnancy , Primary Cell Culture , Receptors, Dopamine D1/metabolism , Substantia Nigra/cytology , Substantia Nigra/embryology
2.
JIMD Rep ; 16: 57-64, 2014.
Article in English | MEDLINE | ID: mdl-24997713

ABSTRACT

Acute intermittent porphyria (AIP), variegate porphyria (VP), and hereditary coproporphyria (HCP) are caused by mutations in the hydroxymethylbilane synthase (HMBS), protoporphyrinogen oxidase (PPOX), and coproporphyrinogen oxidase (CPOX) genes, respectively. This study aimed to identify mutations in seven Bulgarian families with AIP, six with VP, and one with HCP. A total of 33 subjects, both symptomatic (n = 21) and asymptomatic (n = 12), were included in this study. The identification of mutations was performed by direct sequencing of all the coding exons of the corresponding enzymes in the probands. The available relatives were screened for the possible mutations. A total of six different mutations in HMBS were detected in all seven families with AIP, three of which were previously described: c.76C>T [p.R26C] in exon 3, c.287C>T [p.S96F] in exon 7, and c.445C>T [p.R149X] in exon 9. The following three novel HMBS mutations were found: c.345-2A>C in intron 7-8, c.279-280insAT in exon 7, and c.887delC in exon 15. A total of three different novel mutations were identified in the PPOX gene in the VP families: c.441-442delCA in exon 5, c.917T>C [p.L306P] in exon 9, and c.1252T>C [p.C418R] in exon 12. A novel nonsense mutation, c.364G>T [p.E122X], in exon 1 of the CPOX gene was identified in the HCP family. This study, which identified mutations in Bulgarian families with AHP for the first time, established seven novel mutation sites. Seven latent carriers were also diagnosed and, therefore, were able to receive crucial counseling to prevent attacks.

3.
Biol Psychiatry ; 69(8): 788-94, 2011 Apr 15.
Article in English | MEDLINE | ID: mdl-21334601

ABSTRACT

BACKGROUND: Omega-3 polyunsaturated fatty acids, including docosahexaenoic acid (DHA), have antidepressant and promnemonic functions. The mechanisms of such activities are still elusive and may involve retinoid X receptors (RXRs), transcription factors known to bind DHA in vitro. METHODS: Promnemonic and antidespair activities of acute DHA treatment were tested in BALBcByJ mice using spontaneous alternation and forced swim test, respectively. The involvement of retinoid receptors in such DHA activities was investigated using RXR and/or retinoic acid receptor (RAR) agonists to mimic DHA activities or a synthetic pan-RXR antagonist to block them. Involvement of RXR isotypes was analyzed using the same tasks and delayed nonmatch to place for working memory in RXRγ knockout mice. RESULTS: Docosahexaenoic acid decreased despair behavior and improved working memory in BALBcByJ mice. Such effects were suppressed by co-treatment with BR1211, a pan-RXR antagonist, whereas a pan-RXR agonist, UVI2108, mimicked DHA activities. Retinoic acid (RA), a natural ligand of RXRs, also reduced despair behavior and improved working memory and such activities did not require activation of RARs, as RA effects were abolished by co-treatment with BR1211 and they were not reproduced by TTNPB, a pan-RAR agonist. The RXRγ knockout mice displayed increased despair and deficits in working memory, which were insensitive to DHA and pan-RXR agonist treatments, whereas DHA or UVI2108 reversed these deficits in RXRγ heterozygous mice. CONCLUSIONS: Our data suggest that RXRs are a converging point in mediating DHA and RA modulations of despair behavior and working memory and that RXRγ is the predominant RXR isotype in these regulations.


Subject(s)
Behavior, Animal/physiology , Depression/metabolism , Docosahexaenoic Acids/pharmacology , Memory, Short-Term/physiology , Retinoid X Receptor gamma/metabolism , Analysis of Variance , Animals , Behavior, Animal/drug effects , Depression/genetics , Memory, Short-Term/drug effects , Mice , Mice, Knockout , Retinoid X Receptor gamma/genetics
4.
Neuron ; 66(6): 908-20, 2010 Jun 24.
Article in English | MEDLINE | ID: mdl-20620876

ABSTRACT

Abnormal signaling by retinoids or n-3 polyunsaturated fatty acids has been implicated in clinical depression. The converging point in activities of these two classes of molecules is transcriptional activation of retinoid X receptors (Rxr). We show here that ablation of Rxrgamma in mice leads to depressive-like behaviors including increased despair and anhedonia, which were accompanied by reduced expression of dopamine D2 receptor in the shell of nucleus accumbens (NAc) and altered serotonin signaling. While abnormal serotonin signaling is not sufficient to generate the depressive behaviors, increasing D2r expression by chronic fluoxetine (Prozac) treatment or adenoassociated virus type2 (AAV2) mediated expression of Rxrgamma or D2r in the NAc of Rxrgamma(-/-) mice normalizes depressive-like behaviors in Rxrgamma(-/-) animals. Conversely, NAc infusion of raclopride, a D2r antagonist prevents AAV2-Rxrgamma-mediated rescue of despair behaviors in Rxrgamma(-/-) mice. Combined, our data argue that control of NAc D2r expression is critical for Rxrgamma-mediated modulation of affective behaviors.


Subject(s)
Dopamine/metabolism , Gene Expression Regulation/genetics , Mood Disorders/genetics , Retinoid X Receptor gamma/physiology , Signal Transduction/genetics , Animals , Antidepressive Agents/therapeutic use , Behavior, Animal/physiology , Cell Count/methods , Dependovirus/physiology , Disease Models, Animal , Dopamine/genetics , Dopamine Antagonists/pharmacology , Dose-Response Relationship, Drug , Fluoxetine/therapeutic use , Food Preferences/drug effects , Gene Expression Regulation/drug effects , Haloperidol/pharmacology , Immobility Response, Tonic/physiology , Mice , Mice, Knockout , Mood Disorders/drug therapy , Nucleus Accumbens/drug effects , Nucleus Accumbens/metabolism , Proto-Oncogene Proteins c-fos/genetics , Proto-Oncogene Proteins c-fos/metabolism , RNA, Messenger/metabolism , Receptors, Dopamine D2/metabolism , Receptors, Retinoic Acid/deficiency , Retinoid X Receptor gamma/deficiency , Serotonin/metabolism
SELECTION OF CITATIONS
SEARCH DETAIL
...